港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

靖因药业（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

靖因药业IPO：32项重大专利未获授权靠非经常损益扭亏只是昙花一现？

靖因药业冲击IPO，聚焦小核酸创新药领域，尚未有产品获批

腾讯参股靖因药业港股IPO：核心产品尚处临床阶段II期，部分研发依赖合作方

靖因药业闯关港交所，两年合计亏损6.5亿元

新股前瞻|近9亿美元BD叠加重磅siRNA疗法，靖因药业能否敲开港交所大门？

小核酸公司靖因药业港交所递表：上半年扭亏，暂无商业化产品收入

新股消息 | 靖因药业递表港交所，以siRNA疗法赋能慢性病管理范式转变

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91273/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"91273","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91273\",,,,,undefined,":{"symbol":"91273","market":"HK","secType":"STK","nameCN":"靖因药业（临时代码）","latestPrice":0,"timestamp":1774339200000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":0,"latestTime":"03-24 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":0,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774315800000,1774324800000],[1774328400000,1774339200000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91273\",,,,,undefined,":{"symbol":"91273","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91273\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91273\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91273\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91273\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583526498","title":"靖因药业IPO：32项重大专利未获授权 靠非经常损益扭亏只是昙花一现 ？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526498","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583526498?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 13:38","pubTimestamp":1763098680,"startTime":"0","endTime":"0","summary":"　　近日，靖因药业正式向港交所递交了上市申请，高盛、海通国际及汇丰担任联席保荐人。招股书显示，靖因药业成立于2021年，致力于siRNA疗法开发。知识产权方面，多项核心专利悬而未决，技术护城河尚未建成。　　此外，截至最后可行日期，靖因药业拥有65项专利和专利申请，但其中仅有一项“多核苷酸构建体”专利获得授权。包括32项对集团业务而言属重大的专利在全球均处于“待决”状态。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkanu9175307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91273"],"gpt_icon":0},{"id":"2581001744","title":"靖因药业冲击IPO，聚焦小核酸创新药领域，尚未有产品获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001744","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001744?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 17:19","pubTimestamp":1762334385,"startTime":"0","endTime":"0","summary":"两年半亏损6.16亿元","market":"us","thumbnail":"https://img2.gelonghui.com/3373a-96b9ebbd-26fe-43d3-97c1-7fca2215368e.jpg?guru_height=927&guru_width=1608&guru_size=135992","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/3373a-96b9ebbd-26fe-43d3-97c1-7fca2215368e.jpg?guru_height=927&guru_width=1608&guru_size=135992"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3137174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","BK1161","91273","BK1574"],"gpt_icon":0},{"id":"2577371626","title":"腾讯参股靖因药业港股IPO：核心产品尚处临床阶段II期，部分研发依赖合作方","url":"https://stock-news.laohu8.com/highlight/detail?id=2577371626","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577371626?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 16:54","pubTimestamp":1761209646,"startTime":"0","endTime":"0","summary":"靖因药业致力于siRNA疗法开发，不过目前仍处于临床阶段，尚无营业收入。此后，多款siRNA药物相继成功上市，目前，全球主要市场已有7款siRNA产品获批上市。据招股书，靖因药业的主要产品资产包括SRSD107、SRSD216、SRSD384等。该产品目前正处于欧洲II期多中心临床试验阶段，并计划在中国及澳大利亚/新西兰启动另一项II期试验。未来，靖因药业能否在技术、产品等方面占据长久优势，与CRISPR等伙伴的合作效益有多大，核心产品何时实现商业化突围，都还存在变数。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1761209425076239506","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2045819591.USD","LU0823038988.USD","LU0516423091.SGD","LU1282648689.USD","IE00BQXX3C00.GBP","LU0588545904.SGD","LU1211504680.USD","LU0348816934.USD","LU1719994722.HKD","LU0456842615.SGD","LU0918141887.USD","LU0348827113.USD","91273","LU0823041008.USD","IE00B0169N27.USD","IE0032834883.USD","LU0577902611.USD","LU0823426480.USD","LU0441854154.USD","TCHmain","LU0348735423.USD","IE00BGV7N243.SGD","LU0823426308.USD","LU2462611646.USD","SGXZ99366536.SGD","IE00B5MMRT66.SGD","LU0823039010.USD","LU1504937902.USD","HTCD.SI","IE00B0JY6N72.USD","IE0032431581.USD","LU0675040207.SGD","LU2106854487.HKD","BK1610","LU0634319403.HKD","LU1008478684.HKD","LU1048596156.SGD","LU0072913022.USD","BK1609","LU2237443465.HKD","LU1481107354.HKD","LU0320764755.SGD","LU0862451753.SGD","LU0132412106.USD","LU1974910355.USD","LU0449509016.USD","SG9999002463.SGD","LU2778985437.USD"],"gpt_icon":1},{"id":"2573694679","title":"靖因药业闯关港交所，两年合计亏损6.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573694679","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573694679?lang=zh_cn&edition=fundamental","pubTime":"2025-10-05 11:53","pubTimestamp":1759636380,"startTime":"0","endTime":"0","summary":"　　港交所官网信息显示，靖因药业9月28日递交招股书，高盛、海通国际、汇丰为联席保荐人。靖因药业于2021年由OrbiMed Entities及 Creacion Ventures联合创立，是一家创新生物技术公司，聚焦新一代核酸创新疗法在心血管疾病领域的开发。靖因药业获此轮融资后估值为2.53亿美元。　　控股股东方面，OrbiMed实体是靖因药业的控股股东。62岁的冀群升持有靖因药业5.87%的股权，并担任公司的执行董事兼首席执行官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2025-10-05/doc-infsvfqr5327789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91273","HEXmain"],"gpt_icon":0},{"id":"2571309783","title":"新股前瞻|近9亿美元BD叠加重磅siRNA疗法，靖因药业能否敲开港交所大门？","url":"https://stock-news.laohu8.com/highlight/detail?id=2571309783","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571309783?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 23:04","pubTimestamp":1759158280,"startTime":"0","endTime":"0","summary":"今年9月2日，诺华与Arrowhead就siRNA疗法ARO-SNCA达成一项2亿美元首付款以及后续高达20亿美元潜在里程碑付款的BD交易。实际上，早在今年5月，全球基因编辑巨头CRISPR Therapeutics斥资8.95亿美元与国内创新药企靖因药业达成重磅合作，携手推进siRNA创新疗法的开发。也正是因此BD履历在前，让靖因药业的港股IPO备受关注。而在良好的临床数据支撑下，SRSD107这一siRNA疗法有望获得广阔的商业化市场空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","91273"],"gpt_icon":0},{"id":"2571305623","title":"小核酸公司靖因药业港交所递表：上半年扭亏，暂无商业化产品收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2571305623","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571305623?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 18:35","pubTimestamp":1759142100,"startTime":"0","endTime":"0","summary":"9月28日，靖因药业向港交所递交上市申请，由OrbiMed Entities及Creacion Ventures于2021年联合创立，设双总部于圣地亚哥和上海，聚焦siRNA领域。其核心产品SRSD107是靶向凝血因子XI的siRNA药物，处于二期临床，今年5月与CRISPR Therapeutics达成合作，预先获得2500万美元现金及价值约7000万美元股票，并有资格获超8亿美元里程碑付款。据报告，2024年全球siRNA疗法市场规模达24亿美元，预计2040年将增至503亿美元。业绩上，靖因药业暂无收入，2023、2024年亏损，2025年上半年扭亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092918493197b0c513&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092918493197b0c513&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0314109678.HKD","LU0327786744.USD","LU0043850808.USD","LU0651947912.USD","LU1993786604.SGD","LU2449936058.SGD","LU1328277881.USD","LU0819123356.HKD","HKXCY","LU0516422440.USD","LU0169518387.USD","BK1131","LU1734074674.USD","IE00B3T34201.USD","LU0140636845.USD","HEXmain","LU1981816686.USD","LU1481107354.HKD","BK1589","LU1242518857.USD","LU1044876610.USD","LU1044874839.SGD","00388","LU0417516902.SGD","LU0149534421.HKD","LU0648948544.HKD","LU0918141705.HKD","LU1282649067.USD","LU0572944931.SGD","LU0594300179.USD","LU0516422366.SGD","91273","LU0165289439.USD","LU1813983027.USD","LU0918141887.USD","LU1282649141.HKD","LU1807302812.USD","80388","LU0348814723.USD","LU0762542818.HKD","LU0106959298.USD","LU1366334578.USD","LU0516423091.SGD","LU0084288322.USD","LU1642822792.SGD","LU1105468828.SGD","LU1044875133.USD","LU0370786039.SGD","LU0821914370.USD"],"gpt_icon":0},{"id":"2571878854","title":"新股消息 | 靖因药业递表港交所，以siRNA疗法赋能慢性病管理范式转变","url":"https://stock-news.laohu8.com/highlight/detail?id=2571878854","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571878854?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 07:11","pubTimestamp":1759101067,"startTime":"0","endTime":"0","summary":"招股书显示，靖因药业是一家全球临床阶段生物技术公司，致力于充分发挥siRNA疗法的临床及商业价值。公司以三大潜在重磅产品管线组合、专有siRNA技术平台及全球合作网络为战略基石，旨在通过开发针对全球巨大未满足医疗需求的同类首创与同类最优siRNA 疗法，革新慢性疾病的现行治疗标准。siRNA疗法的开发标志着医学领域直接从核酸层面解决疾病机制的根本性转变。siRNA疗法为慢性病管理带来范式转变，具备三项确定性优势。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91273"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}